Skip to Main Content

Paper Details

Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Neuro Oncol
97
2021
Author NameAffiliation
Motoo NaganeKyorin University Faculty of Medicine
Naoki ShinojimaKumamoto University Hospital
Ryo NishikawaSaitama Medical University International Medical Center
  • 1 - 3

Datasets

Release 1.2